Albireo Pharma Inc Stock News

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndro

The market is moving higher, and these small companies are helping.

Albireo Pharma, Inc. (NASDAQ:ALBO ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director, LifeSci Advisors Ron Cooper - President and Chie

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS)

Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET

Sales for Bylvay's first approved indication is increasing. The company recently posted superb data for an orphan disease known as Alagille Syndrome.

Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.

Shares of Albireo Pharma Inc. ALBO, +6.86% gained 10.4% in premarket trading on Tuesday after the company said it is seeking Food and Drug Administration approval to use its medication Bylvay as a tre

Albireo Pharma, Inc. is expanding its Bylvay label for two other rare liver conditions, biliary atresia and Alagille syndrome. The company is poised to report topline data for the Phase 3 (ASSERT) tri

Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near te

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today an

Albireo Pharma, Inc. (NASDAQ:ALBO ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Ron Cooper - CEO, President & Director Pamela Step

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?